Capecitabine (Xeloda)

10/01/2020 - "Capecitabine had the best efficacy against endocrine-resistant breast cancer."
01/01/2001 - "Capecitabine is an important new treatment option for breast cancer patients, and ongoing clinical trials should further define its role in a range of settings."
01/01/2021 - "Primary analysis of the phase III trial BG01-1323L demonstrated that utidelone plus capecitabine significantly improved progression-free survival (PFS) and overall response rate (ORR) versus capecitabine alone in heavily-pretreated patients with metastatic breast cancer (MBC). "
01/01/2016 - "Combining capecitabine with standard (neo)adjuvant regimens in early breast cancer demonstrated a significantly superior OS, and indicated DFS improvement in some subtypes with high risk of recurrence. "
01/01/2012 - "We found significant improvement in the additional capecitabine arm versus control in disease-free survival (DFS) (HR = 0.83, 95% CI: 0.71-0.98, P = 0.027), overall survival (OS) (HR = 0.71, 95% CI: 0.57-0.88, P = 0.002), distant recurrence (HR = 0.79, 95% CI: 0.66-0.94, P = 0.008) and the death from breast cancer only (HR = 0.65, 95% CI: 0.51-0.83, P = 0.001). "

02/01/2023 - "The successful PDX model was selected to study the efficacy of capecitabine in treating colorectal cancer. "
04/01/2010 - "To date, the economic evaluation literature has consistently projected or found that capecitabine is not only a cost-effective treatment for adjuvant or for metastatic colorectal cancer (i.e., providing good value for money) but, furthermore, would actually be cost saving in the majority of country settings."
01/01/2007 - "Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (mCRC). "
06/01/2004 - "Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (MCRC). "
01/01/2009 - "Modifying the capecitabine dosing schedule from 14 days on, 7 days off (14/7) to 7 days on, 7 days off (7/7) may enable higher doses and improved antitumor efficacy in colorectal cancer xenografts. "

01/01/2009 - "In the HT29 model, tumor growth inhibition and increase in life span (ILS) were significantly greater with capecitabine 7/7 than with 14/7 (P<0.05). "
02/15/1998 - "The efficacy of capecitabine would be optimized by selecting patients who have tumors with a high ratio of dThdPase to DPD activities."
01/01/2010 - "Subsequent preclinical studies demonstrated that this biweekly capecitabine schedule allowed for safe delivery of higher daily doses, improved tumor response, and prolonged animal survival. "
03/01/2021 - "Our findings suggest that PBPM is effective for addressing capecitabine-related HFS among cancer patients aged higher than 70 years, in that it helps prevent an increase in HFS severity."
01/01/2016 - "Receipt of either FOLFOX or capecitabine was correlated with improved cancer-specific survival, disease-free survival, and overall survival compared with surgery alone; this effect was not modified by age. "

10/01/2012 - "S-1 and capecitabine are orally administered fluoropyridines reported to be effective in the treatment of advanced gastric cancer(AGC). "
01/01/2021 - "Probiotic Lactobacillus rhamnosus Supplementation Improved Capecitabine Protective Effect against Gastric Cancer Growth in Male BALB/c Mice."
01/01/2003 - "Capecitabine was suggested to be safe and effective in the treatment of advanced or recurrent gastric cancer. "
03/01/2009 - "Several trials have demonstrated the safety and efficacy of regimens combining capecitabine with other known active drugs against gastric cancer in doublet and triplet combinations. "
08/19/2008 - "A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer."

02/01/2006 - "Preoperative chemoradiation with capecitabine and RT appeared to be effective in locally advanced resectable, rectal cancer. "
08/01/2016 - "Preoperative chemoradiation with capecitabine for rectal cancer in elderly patients: a phase I trial."
12/01/2014 - "Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study."
08/15/2011 - "The authors reported the final results of this single institution prospective randomized phase 3 trial comparing preoperative CRT with postoperative CRT using capecitabine in survival, local control, sphincter preservation, and toxicity for the treatment of locally advanced rectal cancer. "
09/29/2010 - "This study confirms data from other non-randomised studies that capecitabine-based preoperative chemoradiation is a feasible treatment option for locally advanced rectal cancer, with positive 5-year overall survival, recurrence-free survival, and local control rates."